A federal judge has denied a bid by Sanofi-Aventis to halt sales of a generic version of its blockbuster blood thinner Lovenox, a move which may help pave the way for the Food and Drug Administration to approve generic biologic drugs.
In a 33-page opinion issued last night, Judge Emmet Sullivan of U.S. District Court for the District of Columbia found Sanofi failed to show the FDA had acted unreasonably in approving an application by Sandoz Inc. to make generic Lovenox. He denied Sanofi’s request for a preliminary injunction that would have forced the FDA to rescind approval of the generic, which has been on the market for a month.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
